Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy
Breccia M et al. Haematologica, May 2026 (epub ahead of print) – open access publication
Link to full abstract